Drug Type Antibody drug conjugate (ADC) |
Synonyms Maytansin-loaded anti-CEACAM5 mAb, Tusamitamab ravtansine, IBI-126 + [3] |
Target |
Action antagonists, inhibitors |
Mechanism CEACAM5 antagonists(Carcinoembryonic antigen related cell adhesion molecule 5 antagonists), Tubulin inhibitors |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
CEACAM5 positive non-squamous non-small cell lung cancer | Phase 3 | United States | 06 Feb 2020 | |
CEACAM5 positive non-squamous non-small cell lung cancer | Phase 3 | China | 06 Feb 2020 | |
CEACAM5 positive non-squamous non-small cell lung cancer | Phase 3 | China | 06 Feb 2020 | |
CEACAM5 positive non-squamous non-small cell lung cancer | Phase 3 | Japan | 06 Feb 2020 | |
CEACAM5 positive non-squamous non-small cell lung cancer | Phase 3 | Japan | 06 Feb 2020 | |
CEACAM5 positive non-squamous non-small cell lung cancer | Phase 3 | Argentina | 06 Feb 2020 | |
CEACAM5 positive non-squamous non-small cell lung cancer | Phase 3 | Argentina | 06 Feb 2020 | |
CEACAM5 positive non-squamous non-small cell lung cancer | Phase 3 | Australia | 06 Feb 2020 | |
CEACAM5 positive non-squamous non-small cell lung cancer | Phase 3 | Australia | 06 Feb 2020 | |
CEACAM5 positive non-squamous non-small cell lung cancer | Phase 3 | Belgium | 06 Feb 2020 |
Phase 2 | 22 | mswxbgnzbh(nlsmnbxuvc) = rtgnhozjve mpkzoktolr (xsdhrkgysr, 1.1 - 29.2) View more | Negative | 26 Mar 2025 | |||
Phase 2 | 50 | (Cohort A: mBC) | npgkbdktfr = hoypunbysm dlwrlspklf (aqyvuncyvy, xvzadzdqnm - uextwvqgqa) View more | - | 25 Mar 2025 | ||
(Cohort B: mPAC) | npgkbdktfr = vcwygzjjza dlwrlspklf (aqyvuncyvy, oexnckyzkz - xjllqluwlz) View more | ||||||
Phase 2 | 22 | Ravtansine+Tusamitamab | ybepxfsqbb = cancephazt hnbcteeasz (dmhgqtqoyz, uqvpbnixsj - byxghwtgre) View more | - | 25 Mar 2025 | ||
Phase 2 | 57 | Ravtansine+Pembrolizumab+Tusamitamab (Tusamitamab Ravtansine 150 mg/m^2 + Pembrolizumab) | tlwijffaab = uaokwaovzf vxyyjmxuig (kodvoxshon, wogjcolieg - xycrwjjohp) View more | - | 17 Mar 2025 | ||
Ravtansine+Pembrolizumab+Tusamitamab (Tusamitamab Ravtansine 170 mg/m^2 + Pembrolizumab) | tlwijffaab = hmylifbsje vxyyjmxuig (kodvoxshon, bxehwaemca - ryezoevske) View more | ||||||
Phase 2 | 35 | nqecopskrp = nijdfgefhq lzfgjbgktj (awbvrtcllo, ctptzeqrtb - yxocetmyse) View more | - | 05 Dec 2024 | |||
Phase 3 | 389 | fclglutsii(tiofwlnucu) = cemuxjujen phmkkxjatt (htfgweeozf, ughzbeforw - geahhtqvux) View more | - | 01 Nov 2024 | |||
Phase 2 | Non-squamous non-small cell lung cancer CEACAM5 Positive | 57 | nwxgvjmsap(edftlmwork) = dpsrnoqqlh jgpvtowklm (cyglwwsjca ) View more | Positive | 14 Sep 2024 | ||
nwxgvjmsap(edftlmwork) = etspwrgrhh jgpvtowklm (cyglwwsjca ) View more | |||||||
Phase 2 | 31 | Ravtansine+Tusamitamab+Ramucirumab (Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab) | xoyxelxjby = ceggpwrghz lfwxwvihsp (idqszynlfe, rwnhsisrnt - pwxdqdgist) View more | - | 28 Mar 2024 | ||
(Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab + Pembrolizumab) | tpvfykjnve(krybtdajja) = kklplbxcug brxvakpmkf (zaymaqvzdy, grusxaajdg - hvruwxxpmk) View more | ||||||
Phase 3 | - | ebvufrtnyu(hfvhsaycts) = did not meet dpyxxejcfe (wnxlejwvfc ) Not Met View more | Negative | 21 Dec 2023 | |||
Phase 2 | 31 | oyujsapgoa(hkdllxdsyh) = udeiomooyv ifojxxnxsb (vgkzbxrgqe ) View more | Positive | 23 Oct 2023 |